Madrigal Pharmaceuticals, Inc. (MDGL)Healthcare | Biotechnology | West Conshohocken, United States | NasdaqGS
533.76 USD
-9.93
(-1.826%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 533.76 |
Hot Take ↕ | Aug. 22, 2026, 4:35 a.m. EDT
Madrigal presents a compelling high-growth narrative backed by robust revenue expansion and a formidable balance sheet, yet it remains a speculative investment due to persistent losses and negative cash flow. The company is executing well on its pipeline, evidenced by the recent Phase 1 trial initiation for a GLP-1 drug and strong growth in its core Rezdiffra franchise, which analysts reward with a strong buy recommendation and a price target nearly 30 percent higher than the current level. However, the stock trades at a premium valuation with no income component, meaning investors must rely entirely on future profitability and clinical success for returns. While the long-term trajectory shows massive appreciation over the last nine years, the current financials indicate the business is still in a capital-intensive development phase. For investors, this is a high-conviction growth play suitable for those comfortable with volatility, rather than a stable income vehicle. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.038544 |
| MSTL | 0.038594 |
| AutoETS | 0.038950 |
| AutoTheta | 0.053874 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 59% |
| H-stat | 0.33 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.019 |
| Excess Kurtosis | 1.04 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 66.4 |
| Revenue per Share | 56.147 |
| Market Cap | 12,332,058,624 |
| Forward P/E | 55.46 |
| Beta | -1.00 |
| Profit Margins | -25.32% |
| Website | https://www.madrigalpharma.com |
As of Aug. 22, 2026, 4:35 a.m. EDT: Speculators are positioning for high volatility with elevated implied volatility across all expirations. Call buyers are heavily favoring out-of-the-money strikes above the current price, particularly in the six-month to one-year horizon, indicating a bet on significant upside catalysts. Put buyers are also active, creating a straddle-like environment where investors are hedging against downside risk while simultaneously seeking explosive gains. The heavy open interest at strikes significantly above the current price suggests a consensus expectation of a binary event or major approval milestone.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.24668086 |
| Address1 | 1,001 Conshohocken State Road |
| Address2 | Suite 2-350 |
| All Time High | 615.0 |
| All Time Low | 5.25 |
| Ask | 512.55 |
| Ask Size | 1 |
| Audit Risk | 2 |
| Average Daily Volume10 Day | 246,570 |
| Average Daily Volume3 Month | 359,141 |
| Average Volume | 359,141 |
| Average Volume10Days | 246,570 |
| Beta | -1.003 |
| Bid | 511.93 |
| Bid Size | 1 |
| Board Risk | 3 |
| Book Value | 22.678 |
| City | West Conshohocken |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 5 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 533.76 |
| Current Ratio | 3.205 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 542.16 |
| Day Low | 528.285 |
| Debt To Equity | 66.4 |
| Display Name | Madrigal Pharmaceuticals |
| Dividend Date | 1,469,404,800 |
| Earnings Call Timestamp End | 1,785,412,800 |
| Earnings Call Timestamp Start | 1,785,412,800 |
| Earnings Timestamp | 1,785,414,600 |
| Earnings Timestamp End | 1,793,795,400 |
| Earnings Timestamp Start | 1,793,795,400 |
| Ebitda | -321,097,984 |
| Ebitda Margins | -0.25009 |
| Enterprise To Ebitda | -36.877 |
| Enterprise To Revenue | 9.222 |
| Enterprise Value | 11,841,056,768 |
| Eps Current Year | -6.4925 |
| Eps Forward | 9.625 |
| Eps Trailing Twelve Months | -13.74 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 525.8402 |
| Fifty Day Average Change | 7.9198 |
| Fifty Day Average Change Percent | 0.015061229 |
| Fifty Two Week Change Percent | 24.668085 |
| Fifty Two Week High | 615.0 |
| Fifty Two Week High Change | -81.23999 |
| Fifty Two Week High Change Percent | -0.13209754 |
| Fifty Two Week Low | 393.61 |
| Fifty Two Week Low Change | 140.15002 |
| Fifty Two Week Low Change Percent | 0.3560632 |
| Fifty Two Week Range | 393.61 - 615.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,170,772,200,000 |
| Float Shares | 13,724,313 |
| Forward Eps | 9.625 |
| Forward P E | 55.455585 |
| Free Cashflow | -80,466,248 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 915 |
| Fullday Change | -9.92999 |
| Fullday Change Percent | -1.82641 |
| Fullday Price | 533.76 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.91476995 |
| Gross Profits | 1,174,515,968 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.058769997 |
| Held Percent Institutions | 1.04431 |
| Implied Shares Outstanding | 23,104,126 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ir Website | http://ir.syntapharma.com/phoenix.zhtml?c=147988&p=irol-irhome |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,469,404,800 |
| Last Split Factor | 1:35 |
| Long Business Summary | Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania. |
| Long Name | Madrigal Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 12,332,058,624 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_144939852 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -325,095,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 12,561,251,223 |
| Number Of Analyst Opinions | 16 |
| Open | 539.38 |
| Operating Cashflow | -197,716,000 |
| Operating Margins | -0.15459 |
| Overall Risk | 5 |
| Payout Ratio | 0.0 |
| Phone | 267 824 2827 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 533.76 |
| Post Market Time | 1,787,959,804 |
| Previous Close | 543.69 |
| Price Eps Current Year | -82.211784 |
| Price Hint | 2 |
| Price To Book | 23.536469 |
| Price To Sales Trailing12 Months | 9.6048565 |
| Profit Margins | -0.2532 |
| Quick Ratio | 2.755 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -9.92999 |
| Regular Market Change Percent | -1.82641 |
| Regular Market Day High | 542.16 |
| Regular Market Day Low | 528.285 |
| Regular Market Day Range | 528.285 - 542.16 |
| Regular Market Open | 539.38 |
| Regular Market Previous Close | 543.69 |
| Regular Market Price | 533.76 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 268,663 |
| Return On Assets | -0.17844 |
| Return On Equity | -0.53306997 |
| Revenue Growth | 0.712 |
| Revenue Per Share | 56.147 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 23,104,126 |
| Shares Percent Shares Out | 0.0877 |
| Shares Short | 2,025,404 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,062,862 |
| Short Name | Madrigal Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.103 |
| Short Ratio | 5.49 |
| Source Interval | 15 |
| State | PA |
| Symbol | MDGL |
| Target High Price | 962.0 |
| Target Low Price | 543.0 |
| Target Mean Price | 678.0625 |
| Target Median Price | 651.5 |
| Total Cash | 838,753,024 |
| Total Cash Per Share | 36.303 |
| Total Debt | 347,751,008 |
| Total Revenue | 1,283,939,968 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -13.74 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 514.9031 |
| Two Hundred Day Average Change | 18.856934 |
| Two Hundred Day Average Change Percent | 0.036622297 |
| Type Disp | Equity |
| Volume | 268,663 |
| Website | https://www.madrigalpharma.com |
| Zip | 19,428 |